Biogen Reiterates Byooviz Will Not Be Meaningful In 2022
Launches Outside Of The US Scheduled For Early 2023
Biogen is looking for its ranibizumab biosimilar Byooviz to make a splash in 2023 as it continues to forecast falling biosimilars sales for 2022.
You may also be interested in...
Xbrane has resubmitted its filing for a ranibizumab biosimilar version of Lucentis to the FDA, suggesting that it could receive approval in the first half of next year.
April brings news of further biosimilar competition to Lucentis in major European markets.
Biogen expects impending biosimilar launches to stimulate new growth, while unfavorable market conditions have taken their toll on the company.